DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2015/0250896 A1 Zhao (43) Pub

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2015/0250896 A1 Zhao (43) Pub US 20150250896A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0250896 A1 Zhao (43) Pub. Date: Sep. 10, 2015 (54) HYDROPHILIC LINKERS AND THEIR USES Publication Classification FOR CONUGATION OF DRUGS TO A CELL (51) Int. Cl BNDING MOLECULES A647/48 (2006.01) (71) Applicant: Yongxin R. ZHAO, Henan (CN) Ek E. 30.8 C07D 207/216 (2006.01) (72) Inventor: R. Yongxin Zhao, Lexington, MA (US) C07D 40/12 (2006.01) C07F 9/30 (2006.01) C07F 9/572 (2006.01) (73) Assignee: Hangzhou DAC Biotech Co., Ltd., (52) U.S. Cl. Hangzhou City, ZJ (CN) CPC ........... A61K47/48715 (2013.01); C07F 9/301 (2013.01); C07F 9/65583 (2013.01); C07F (21) Appl. No.: 14/432,073 9/5721 (2013.01); C07D 207/46 (2013.01); C07D 401/12 (2013.01); A61 K3I/454 (22) PCT Filed: Nov. 24, 2012 (2013.01) (86). PCT No.: PCT/B2O12/0567OO Cell(57) binding- agent-drugABSTRACT conjugates comprising hydrophilic- S371 (c)(1), linkers, and methods of using Such linkers and conjugates are (2) Date: Mar. 27, 2015 provided. Patent Application Publication Sep. 10, 2015 Sheet 1 of 23 US 2015/0250896 A1 O HMDS OSiMe 2n O Br H-B-H HPC 3 2 COOEt essiop-\5. E B to NH 120 °C, 2h OsiMe3 J 50 °C, 2h eSiO OEt 120 oC, sh 1 2 3. 42% from 1 Bra-11a1'oet - Brn 11-1 or a 1-1 or ÓH 140 °C ÓEt ÓEt 4 5 6 - --Messio. 8 B1a-Br aus 20 cc, hP-1}^-'ot Br1-Y. OEt 3. OEt 7 s a OH OEt 8 S O. O. O. 1). 1N NaOH EtOCSSK ka. He He Moss-a-NM-n1'oet 2), pH 7.5 EtOH OH OEt PySSPy 9 (lisN S1 n^^ --\ou9 -->NHS/EDC ÉllsN S1 Y}-\--\'o-'o' OH OH OH OH O 10 11 Drug-SH, pH 4-7, then O O O Antibodies,noodles, or Proteiroteins "S-S-1-N-N-NOH OH H n = 1 - 20 12 Fig. 1. The synthesis of a di-phosphinic acid linker. Br1Nile -/n aus,OEt -CH(OEt), > Br-al-M1'oetQ Q S-E-M1-\'oet OH OEt OE OEt is OEt OEt 14 2, 120 °C, 2h O O. O. O. EOCSSKw B1a-rB B^{-\-E-MB-n1'oetOH OEt OEt EtOH S 1). 1N NaOH O O. O. O. Fig. 2. The synthesis of a tri-phosphinic acid linker Patent Application Publication Sep. 10, 2015 Sheet 2 of 23 US 2015/0250896 A1 Q 9 O O CH(OEt) O O O O Br-a-ra--M. 1Soet --> B^-\l-MB-n-'oet OH OEt OEt is OEt OEt OEt 19 2, 120 °C, 2h O EtOCSSK Br1N1 - Bru-N-Pro-YrOH oEt OEt OEt OEt EtOH S 1). 1N NaOH 1oss?\-ra-rá-B-B-B-4-1. OEt Her2), pH 7.5 OH OEt OEt OEt PySSPy O O O I I O ÖH OH OH OH 23 O Fig. 3. The synthesis of a tetra-phosphinic acid linker Br1a--M.tallas OE n-i-M}^' of BizshO O Na2CO OEt OEt 13 OEt OEt - O --> DMF, 50 °C O O 8 NHC O O NHSFEDC pAZS-\-\-rottO OEt OEt O -reflux o- Nr-uo"ÖH oH HerDMA 24 25 O O O-N Drug-SH Drug O O e s Cr-y-O OH OH O pH 4 ~7.5 Cr-Y- 26 Antibodies or Proteins Drug O NH mAb pH 5.5-8.5 -N1\-1\--/n O OH OH O n = 1 - 20 Drug-SH 28 9 O O O O O O s Antibodies H O OH OH O pH 6.5-8.5 O OH OH O n = 1 - 20 Fig. 4. The synthesis of a di-phosphinic acid linker. Patent Application Publication Sep. 10, 2015 Sheet 4 of 23 US 2015/0250896 A1 Hs-a-o-O BY-1a-Br Bra-sa-to- 30% H.o2V2 Bra-9-n-to 51 DIPEA, 45°C 52 HOAc/KMnO(cat) 53 0.5 M NaOH { Drug-SH, then He -e as mAb or protein O Drug-YS 56 O O O O O Hs-n-to- Br1n 1B BMs-n-o 30%KMO HOV2 B-1S-1 51 DIPEA, 45°C 57 nu 58 HOA O O O O O HSAC M Y O.S M NaOH SS NHS/EDC DIPEA AcS S O PySSPy,w pH 7.2 NS-S2N, MNS OH HeDCM O 59 O 60 O Drug-SH then s^^ mAh or proteina Drug O O O Ms-\-y -eBr1N1Br, Br-1-s^^s^1/ 64 DIPEA, 45°C 65 30% HO R. HSAe it all it HOA - Br^1-a/n^1 HeDPEA Aesn1-a/n^1 / O O 66 O O 67 r O O O 0.5 MNaOH wa I NHS/EDC PySSPy,SMNne pH 7.2 (CaMaMa'ohNS-S NSEge -e then mAb I'll S N or protein Fig 6. The synthesis of mono-, and di-sulfonyl linkers Patent Application Publication Sep. 10, 2015 Sheet 5 of 23 US 2015/0250896 A1 O MSHw O Br1N1 Br O Br O1 Y - HS-sa-to- e Br1-sa/s-a-o- 51 DIPEA, 45°C 71 72 O O newN"- Brain/S-\'osiO 9 OS M NaOHNag s-Ma-onif Q NHS/EDC 18-crown-6 O 73 O 74 Drug-SH, then O O O -mAb or-o- protein Drug SMS-\-S^ O 0 n = 1 - 20 -e Br M S al O -30% H.O.> Br 1-allS O1 S1 DIPEA, 45°C 77 A. 78 HSA O O OS M NaOH C O O NHS/EDC -eDIPEA, 60°C As YS o? PySSPy, pH 7.2 NS-S a o- DCM D O O 80 Drug-SH,S thenT- Drug SS. Ms N mAb or protein O H 8a n = 1 - 20 B-1o-S-HS/N HS-s^1O o? BY-1N1 On AsaoO S1 DIPEA, 45°C 71 DIPEA, 45°C 82 O O O O 30% HO HSAc HOAc O 83 O O 0.5 M NaOH 1S O O O NHS/EDC PySSPy,-e pH 7.2 ClSNs-s NM-ul-\'oh - DM > O O 85 O O O Drug-SHES- fS Ys 19-v then mAh Drug N or proteino O 87O Hn Fig. 7. The synthesis of mono-, and di-sulfonyl linkers Patent Application Publication Sep. 10, 2015 Sheet 6 of 23 US 2015/0250896 A1 (ho^-oh - HO-o-o-e-C'sO Tso-hoa-o-O 88 m = m1-30 aro<O 89 90 O . no ->AcSH Acs-hoa-o-O in0,5 N NaOH Bry S \-hoo-k 30%HOA H2O, yr. 91 B1a-Br 92 y O O O O 1N1-S EtOCSSK'e MY s^-Sa-ho-ohs^-in-ho OH -o-SSNs Br i-hoon EtOH O O m PySSPy, pH 7.2 O O O O O -- (ys, Min-ho-oh SSPS- (ys, Min-ho-o- N s & 'm DMA S O O O O Br1-in-ho-oh FNN-a-ho-ohEtN y NSFPSNHS/EDC O "97 O m. DMA O O O azyan O Br^-sa-ho-o- YoDMF 7 Az O 100 O 101 30% HO O O 9 O O O. HOA, 60°Ca UN-NSy, r-i-hoon NHS/EDCDMA NYi-hoo O2 O 103 m = 1 - 30 O y HS101al O O1a-'-HO CB/PPh.4 3 Br. Br He Br aul Y ( O l, - DCM as OY pp. Ytors O 104 m = 1--30 105 106 30% HO, SRP R ww S R O HOA > Bra-to-vaul-EtOCSSk O to Mo'ss-to-vy-\'o m-1 107 m 108 '6) R NHS EDC pHpsp- 7.2 SNSSS Vtory-longm-1 DMA 110 m = 1 - 30 Fig. 8. The synthesis of mono-Sulfonyl linkers containing polyethylene glycols. Patent Application Publication Sep. 10, 2015 Sheet 7 of 23 US 2015/0250896 A1 O SH O Br B Tso-foot- HS-EtN Hsn-sa-ho-o- BryllO C-S-foot 90 m = 1 -30 11 EtN, 50°C 12 30% HO,SCS Br R O EtOCSSK J.S Oif 9 O 0.5 M NaOH HOA o'oh to Mo su/~\hoon PySSPy, 113 Ö O 114 pH 7.2 ( VS Qal O NHS/EDC FN 's-?s-in-hoon's 5 O 115 C. A.A ... is . O Sinho'ohO O ES-N-\-shoot NHSEDC 117 ", DMA O He NHS/EDC HOAc, 800C ONvvi{oons O DMA 121 O CBr/PPh B Br HSMSO M ( HO1n-NH DCM4f 13 OYi 138 p 104 m = 1--30 123 DIPEA 30% HO Q9 Q9 Q EtOCSSK S OW. V.O O -eHOAC Br-to SS-N-au-V// Y.EtOH S. M.O s/ton) SyllQ-M1 m-1 f m-1 125 126 0.5 M NaH2 O O. O. O '6)Pyssey, SN’s Svory-roll W pH 7.2 m-1 O 127 NHS/EDC/DMA Fig. 9. The Synthesis of di-sulfonyl linkers containing polyethylene glycols. Patent Application Publication Sep. 10, 2015 Sheet 8 of 23 US 2015/0250896 A1 O O O O 1nSS/NS.2 O O O O. O HaskOBn Br.120 °C, 5h Bill Bruin?O OBnn'o-e- N-S^^*o-8 ÖBn 129 13 131 S O O O EtOCSSK 20%oV CHSOHWDCM 13 SV3 O OBn PySSPy, pH 7.2 O allO O 20% CHSOH 9 O O O OBn 136 M 8 OH 137 DMA 139 m= 1 - 20 O O NaH/DMF RO Q Q Azisi,15 O thenen so,9 AlSz.--SabaoO O OBn 140 20then CHSoHDCy pH 7, 100'C O B-?tO NHS/EDC N1-\- OH - DMA e.
Load more

Recommended publications
  • Estimated Burden of Serious Fungal Infections in Ghana
    Journal of Fungi Article Estimated Burden of Serious Fungal Infections in Ghana Bright K. Ocansey 1, George A. Pesewu 2,*, Francis S. Codjoe 2, Samuel Osei-Djarbeng 3, Patrick K. Feglo 4 and David W. Denning 5 1 Laboratory Unit, New Hope Specialist Hospital, Aflao 00233, Ghana; [email protected] 2 Department of Medical Laboratory Sciences, School of Biomedical and Allied Health Sciences, College of Health Sciences, University of Ghana, P.O. Box KB-143, Korle-Bu, Accra 00233, Ghana; [email protected] 3 Department of Pharmaceutical Sciences, Faculty of Health Sciences, Kumasi Technical University, P.O. Box 854, Kumasi 00233, Ghana; [email protected] 4 Department of Clinical Microbiology, School of Medical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi 00233, Ghana; [email protected] 5 National Aspergillosis Centre, Wythenshawe Hospital and the University of Manchester, Manchester M23 9LT, UK; [email protected] * Correspondence: [email protected] or [email protected] or [email protected]; Tel.: +233-277-301-300; Fax: +233-240-190-737 Received: 5 March 2019; Accepted: 14 April 2019; Published: 11 May 2019 Abstract: Fungal infections are increasingly becoming common and yet often neglected in developing countries. Information on the burden of these infections is important for improved patient outcomes. The burden of serious fungal infections in Ghana is unknown. We aimed to estimate this burden. Using local, regional, or global data and estimates of population and at-risk groups, deterministic modelling was employed to estimate national incidence or prevalence. Our study revealed that about 4% of Ghanaians suffer from serious fungal infections yearly, with over 35,000 affected by life-threatening invasive fungal infections.
    [Show full text]
  • Fundamental Medical Mycology Errol Reiss
    Fundamental Medical Mycology Fundamental Medical Mycology Errol Reiss Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia H. Jean Shadomy Department of Microbiology and Immunology, Virginia Commonwealth University, School of Medicine, Richmond, Virginia G. Marshall Lyon, III Department of Medicine, Division of Infectious Diseases, Emory University, School of Medicine, Atlanta, Georgia A JOHN WILEY & SONS, INC., PUBLICATION This book was written by Errol Reiss in his private capacity. No official support or endorsement by the Centers for Disease Control and Prevention, Department of Health and Human Services is intended, nor should be inferred. Copyright 2012 by Wiley-Blackwell. All rights reserved Published by John Wiley & Sons, Inc., Hoboken, New Jersey Published simultaneously in Canada No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permitted under Section 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the Publisher, or authorization through payment of the appropriate per-copy fee to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, (978) 750-8400, fax (978) 750-4470, or on the web at www.copyright.com. Requests to the Publisher for permission should be addressed to the Permissions Department, John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, (201) 748-6011, fax (201) 748-6008, or online at http://www.wiley.com/go/permission. Limit of Liability/Disclaimer of Warranty: While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose.
    [Show full text]
  • Fig. L COMPOSITIONS and METHODS to INHIBIT STEM CELL and PROGENITOR CELL BINDING to LYMPHOID TISSUE and for REGENERATING GERMINAL CENTERS in LYMPHATIC TISSUES
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date Χ 23 February 2012 (23.02.2012) WO 2U12/U24519ft ft A2 (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, A61K 31/00 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, PCT/US201 1/048297 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (22) International Filing Date: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 18 August 201 1 (18.08.201 1) NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (25) Filing Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (26) Publication Language: English ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/374,943 18 August 2010 (18.08.2010) US kind of regional protection available): ARIPO (BW, GH, 61/441,485 10 February 201 1 (10.02.201 1) US GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, 61/449,372 4 March 201 1 (04.03.201 1) US ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (72) Inventor; and EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, ΓΓ, LT, LU, (71) Applicant : DEISHER, Theresa [US/US]; 1420 Fifth LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Avenue, Seattle, WA 98101 (US).
    [Show full text]
  • HIV-Infected Patients
    New Drugs for the Treatment-Experienced Patient Joseph Eron, md Associate Professor of Medicine and Director, Clinical Core unc Center for aids Research, University of North Carolina at Chapel Hill Summary by Tim Horn Edited by Jay Dobkin, md; Michael Saag, md reatment options for antiretro- humans by adenosine deaminase into D- Deeks and his colleagues in 1998 demon- viral-experienced patients leave a dioxolane guanine (dxg), a metabolite that strated a 1 log reduction in hiv-rna in hiv- lot to be desired. According to Dr. has potent activity against hiv and hbv. infected patients—more than 50% of whom Joe Eron, patients who have treat- According to in vitro data presented at were treatment-experienced—who received ment experience in all three classes the 3rd International Workshop on hiv tenofovir df 300 mg once daily as of currently available antiretrovi- Drug Resistance and Treatment Strategies, monotherapy for 28 days (Deeks, 1998). Trals have, at best, a 30% chance of re- held in June 1999, dapd was found to in- According to in vitro data presented by ducing their viral load to levels below 400 hibit wild-type and mutant isolates resistant Gilead’s Dr. Michael Miller at the recent copies/mL upon initiating a salvage regi- to azt (Retrovir) and 3TC (Borroto-Esoda, 4th International Resistance Workshop, the men. Cross-resistance within each class of 1999). The drug was also reported to be ac- resistance pattern for tenofovir df is simi- drugs, particularly the protease inhibitors tive against strains collected from patients lar to that of its chemical predecessor adefo- (pis) and non-nucleoside reverse tran- who have failed various nrti and nnrti vir, a compound no longer in development scriptase inhibitors (nnrtis), essentially combination therapies, including those for the treatment of hiv (Miller, 2000).
    [Show full text]
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
    [Show full text]
  • Malignant B Lymphocyte Survival in Vivo CD22 Ligand Binding Regulates Normal
    The Journal of Immunology CD22 Ligand Binding Regulates Normal and Malignant B Lymphocyte Survival In Vivo1 Karen M. Haas, Suman Sen, Isaac G. Sanford, Ann S. Miller, Jonathan C. Poe, and Thomas F. Tedder2 The CD22 extracellular domain regulates B lymphocyte function by interacting with ␣2,6-linked sialic acid-bearing ligands. To understand how CD22 ligand interactions affect B cell function in vivo, mouse anti-mouse CD22 mAbs were generated that inhibit CD22 ligand binding to varying degrees. Remarkably, mAbs which blocked CD22 ligand binding accelerated mature B cell turnover by 2- to 4-fold in blood, spleen, and lymph nodes. CD22 ligand-blocking mAbs also inhibited the survival of adoptively transferred normal (73–88%) and malignant (90%) B cells in vivo. Moreover, mAbs that bound CD22 ligand binding domains induced significant CD22 internalization, depleted marginal zone B cells (82–99%), and reduced mature recirculating B cell numbers by 75–85%. The CD22 mAb effects were independent of complement and FcRs, and the CD22 mAbs had minimal effects in CD22AA mice that express mutated CD22 that is not capable of ligand binding. These data demonstrate that inhibition of CD22 ligand binding can disrupt normal and malignant B cell survival in vivo and suggest a novel mechanism of action for therapeutics targeting CD22 ligand binding domains. The Journal of Immunology, 2006, 177: 3063–3073. D22 is a B cell-specific glycoprotein of the Ig superfam- cell surface CD22, IgM, and MHC class II expression on mature B ily expressed on the surface of maturing B cells coinci- cells, whereas normal BCR signaling and Ca2ϩ mobilization are dent with IgD expression (1, 2).
    [Show full text]
  • Therapeutic and Prophylactic Use of Oral, Low-Dose Ifns in Species of Veterinary Interest: Back to the Future
    veterinary sciences Review Therapeutic and Prophylactic Use of Oral, Low-Dose IFNs in Species of Veterinary Interest: Back to the Future Sara Frazzini 1 , Federica Riva 2,* and Massimo Amadori 3 1 Gastroenterology and Endoscopy Unit, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, 20122 Milan, Italy; [email protected] 2 Dipartimento di Medicina Veterinaria, Università degli Studi di Milano, 26900 Lodi, Italy 3 Rete Nazionale di Immunologia Veterinaria, 25125 Brescia, Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-0250334519 Abstract: Cytokines are important molecules that orchestrate the immune response. Given their role, cytokines have been explored as drugs in immunotherapy in the fight against different pathological conditions such as bacterial and viral infections, autoimmune diseases, transplantation and cancer. One of the problems related to their administration consists in the definition of the correct dose to avoid severe side effects. In the 70s and 80s different studies demonstrated the efficacy of cytokines in veterinary medicine, but soon the investigations were abandoned in favor of more profitable drugs such as antibiotics. Recently, the World Health Organization has deeply discouraged the use of antibiotics in order to reduce the spread of multi-drug resistant microorganisms. In this respect, the use of cytokines to prevent or ameliorate infectious diseases has been highlighted, and several studies show the potential of their use in therapy and prophylaxis also in the veterinary field. In this review we aim to review the principles of cytokine treatments, mainly IFNs, and to update the experiences encountered in animals. Keywords: veterinary immunotherapy; cytokines; IFN; low dose treatment; oral treatment Citation: Frazzini, S.; Riva, F.; Amadori, M.
    [Show full text]
  • Afelimomab (Rinn) Ic Medicines Under the Following Names: Adonis V
    2248 Supplementary Drugs and Other Substances Adiphenine Hydrochloride (USAN, rINNM) Adrenalone Hydrochloride (pINNM) ⊗ Uses. The use of aesculus has been reviewed;1,2 although there is some evidence suggesting benefit in chronic venous insuffi- Adiphénine, Chlorhydrate d’; Adiphenini Hydrochloridum; Adrénalone, Chlorhydrate d’; Adrenaloni Hydrochloridum; ciency, more rigorous studies are needed.2 Cloridrato de Adifenina; Hidrocloruro de adifenina; NSC- Adrenalonu chlorowodorek; Hidrocloruro de adrenalona. 1. Sirtori CR. Aescin: pharmacology, pharmacokinetics and thera- 129224; Spasmolytine. Адреналона Гидрохлорид peutic profile. Pharmacol Res 2001; 44: 183–93. Адифенина Гидрохлорид C H NO ,HCl = 217.6. 2. Pittler MH, Ernst E. Horse chestnut seed extract for chronic ve- 9 11 3 nous insufficiency. Available in The Cochrane Database of Sys- C20H25NO2,HCl = 347.9. CAS — 62-13-5. tematic Reviews; Issue 1. Chichester: John Wiley; 2006 (ac- CAS — 50-42-0. ATC — A01AD06; B02BC05. cessed 31/03/06). ATC Vet — QA01AD06; QB02BC05. Profile Preparations Adiphenine and adiphenine hydrochloride have been used as Profile Proprietary Preparations (details are given in Part 3) antispasmodics. Adrenalone hydrochloride is used as a local haemostatic and va- Arg.: Grafic Retard; Herbaccion Venotonico; Nadem; Venastat; Venostasin; soconstrictor. It has also been used with adrenaline in eye drops Austria: Aesculaforce; Provenen; Reparil; Venosin; Venostasin; Belg.: Preparations for glaucoma. Reparil; Veinofytol; Venoplant; Braz.: Phytovein; Reparil; Varilise;
    [Show full text]
  • Patient Resource Free
    PATIENT RESOURCE FREE Third Edition CancerUnderstanding Immunotherapy Published in partnership with CONTENT REVIEWED BY A DISTINGUISHED PRP MEDICAL PATIENT ADVISORY RESOURCE BOARD PUBLISHING® Understanding TABLE OF CONTENTS Cancer Immunotherapy Third Edition IN THIS GUIDE 1 Immunotherapy Today 2 The Immune System 4 Immunotherapy Strategies 6 Melanoma Survivor Story: Jane McNee Chief Executive Officer Mark A. Uhlig I didn’t look sick, so I didn’t want to act sick. Publisher Linette Atwood Having and treating cancer is only one part of your life. Co-Editor-in-Chief Charles M. Balch, MD, FACS Jane McNee, melanoma survivor Co-Editor-in-Chief Howard L. Kaufman, MD, FACS Senior Vice President Debby Easum 7 The Road to Immunotherapy Vice President, Operations Leann Sandifar 8 Cancer Types Managing Editor Lori Alexander, MTPW, ELS, MWC™ 14 Side Effects Senior Editors Dana Campbell Colleen Scherer 15 Glossary Graphic Designer Michael St. George 16 About Clinical Trials Medical Illustrator Todd Smith 16 Cancer Immunotherapy Clinical Trials by Disease Production Manager Jennifer Hiltunen 35 Support & Financial Resources Vice Presidents, Amy Galey Business Development Kathy Hungerford 37 Notes Stephanie Myers Kenney Account Executive Melissa Amaya Office Address 8455 Lenexa Drive CO-EDITORS-IN-CHIEF Overland Park, KS 66214 For Additional Information [email protected] Charles M. Balch, MD, FACS Advisory Board Visit our website at Professor of Surgery, The University of Texas PatientResource.com to read bios of MD Anderson Cancer Center our Medical and Patient Advisory Board. Editor-in-Chief, Patient Resource LLC Editor-in-Chief, Annals of Surgical Oncology Past President, Society of Surgical Oncology For Additional Copies: To order additional copies of Patient Resource Cancer Guide: Understanding Cancer Immunotherapy, Howard L.
    [Show full text]
  • WO 2015/028850 Al 5 March 2015 (05.03.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/028850 Al 5 March 2015 (05.03.2015) P O P C T (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, C07D 519/00 (2006.01) A61P 39/00 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, C07D 487/04 (2006.01) A61P 35/00 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, A61K 31/5517 (2006.01) A61P 37/00 (2006.01) HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, A61K 47/48 (2006.01) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (21) International Application Number: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, PCT/IB2013/058229 SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (22) International Filing Date: TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, 2 September 2013 (02.09.2013) ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (71) Applicant: HANGZHOU DAC BIOTECH CO., LTD UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, [US/CN]; Room B2001-B2019, Building 2, No 452 Sixth TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Street, Hangzhou Economy Development Area, Hangzhou EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, City, Zhejiang 310018 (CN).
    [Show full text]
  • WO 2010/142752 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 16 December 2010 (16.12.2010) WO 2010/142752 Al (51) International Patent Classification: nia 94568 (US). ROBARGE, Kirk D. [US/US]; 1679 C07D 213/75 (2006.01) Λ61K 31/4439 (2006.01) 27th Avenue, San Francisco, California 94122 (US). C07D 401/12 (2006.01) A61K 31/444 (2006.01) STANLEY, Mark S. [US/US]; 284 Lauren Avenue, A61K 31/506 (2006.01) A61P 37/04 (2006.01) Pacifica, California 94044 (US). TSUI, Vickie Hsiao- A61K 31/495 (2006.01) Wei [US/US]; 2626 Martinez Avenue, Burlingame, Cali fornia 94010 (US). WILLIAMS, Karen [GB/GB]; 8/9 (21) International Application Number: Spire Green Centre, Flex Meadow, Harlow, Essex CM 19 PCT/EP2010/058128 5TR (GB). ZHANG, Birong [US/US]; 3060 San Andreas (22) International Filing Date: Drive, Union City, California 94587 (US). ZHOU, Aihe 10 June 2010 (10.06.2010) [US/US]; 1361 Stephen Way, San Jose, California 95129 (US). (25) Filing Language: English (74) Agent: KLOSTERMEYER-RAUBER, Doerte; Gren- (26) Publication Language: English zacherstrasse 124, CH-4070 Basel (CH). (30) Priority Data: (81) Designated States (unless otherwise indicated, for every 61/186,322 11 June 2009 ( 11.06.2009) US kind of national protection available): AE, AG, AL, AM, (71) Applicant (for all designated States except US): F. AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, HOFFMANN-LA ROCHE AG [CWCH]; Grenzacher- CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, strasse 124, CH-4070 Basel (CH).
    [Show full text]
  • As a Registered E-Materials Service User of the EBMT Annual Meeting in Marseille March 26-29Th 2017, You Have Been Granted Permi
    Copyright Statement As a registered E-materials Service user of the EBMT Annual Meeting in Marseille March 26-29th 2017, you have been granted permission to access a copy of the presentation in the following pages for the purpose of scientific education. This presentation is copyrighted material and must not be copied, reproduced, transferred, distributed, leased, licensed, placed in a storage retrieval system, publicly performed or used in any way, except as specifically permitted in writing by the presenter or, as allowed under the terms and conditions under which it was received or as permitted by applicable copyright law or rules of proper citation. Any unauthorised distribution or use of this presentation, a subset of it or graphics taken from the presentation may be a direct infringement of the presenter’s rights. RACE DM training session: Immunusuppressive treatment for aplastic anemia Antonio M. Risitano, M.D., Ph.D. Head of Bone Marrow Transplantation Unit Federico II University of Naples Aplastic anemia Neutrophils for Incidence, age for SCT . Opha disease. Iidee ates peset geogaphi aiatios. to ‐fold highe ates i Asia tha Euope ad the Uited States . Gloal iidee ates age .‐. ases pe illio ihaitats. Aplasti aeia: AA • AA: hat does it ea? • Ho e do the diagosis? • Whe should e teat? • Ho e teat? Aplasti aeia: AA • AA: hat does it ea? • Ho e do the diagosis? • Whe should e teat? • Ho e teat? Aplastic anemia Normal Aplastic anemia CML AA Normal Marrow aplasia Takaku et al, Blood 2010 Takaku et al, Blood 2010 Contraction of stem cell pool Cytopenia AA: hat does it ea? (Oligo) clonal CD8+ T cells Auto-immunity = immune disorder = idiopathic AA AA: hat does it ea? Constitutionnal = inherited disorder (FA, dyskeratosis congenita) Hematopoietic stem cells in AA Hematopoietic progenitor cultures T-cell clonality in aplastic anemia A surrogate marker for Ag-driven immune response Experimental Hematology 23 (1995): 433 Establishment of a CD4+ T cell clone recognizing autologous hematopoietic progenitor cells from a patient with immune-mediated aplastic anemia.
    [Show full text]